| Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights |
– 446 participants completed the brilaroxazine long-term open-label extension (OLE) trial with 156 completing one-year and 301 completing six months of treatment – |
globenewswire.com |
2025-05-15 20:05:00 |
Czytaj oryginał (ang.) |
| Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress |
CUPERTINO, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, announced today topline data from the long-term open label extension portion of the Phase 3 RECOVER study evaluating brilaroxazine in schizophrenia will be presented as part of an oral presentation at the 2025 Congress of the Schizophrenia International Research Society (SIRS) taking place March 29 to April 2, 2025 in Chicago, Illinois, U.S. |
globenewswire.com |
2025-03-30 15:30:00 |
Czytaj oryginał (ang.) |
| Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference |
CUPERTINO, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, taking place virtually February 11-12, 2025. |
globenewswire.com |
2025-02-04 10:00:00 |
Czytaj oryginał (ang.) |
| Reviva to Participate in the 2025 BIO CEO & Investor Conference |
CUPERTINO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a panel discussion at the 2025 BIO CEO & Investor Conference, taking place February 10-11, 2025, in New York, NY. |
globenewswire.com |
2025-01-30 10:00:00 |
Czytaj oryginał (ang.) |
| Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit |
CUPERTINO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a webcasted presentation at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025. |
globenewswire.com |
2025-01-07 10:00:00 |
Czytaj oryginał (ang.) |
| Reviva Announces Proposed Public Offering |
CUPERTINO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock (or common share equivalents in lieu thereof) and warrants to purchase common stock in an underwritten public offering. All of the shares of common stock and warrants are being offered by the Company. |
globenewswire.com |
2024-12-16 19:18:00 |
Czytaj oryginał (ang.) |
| Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low |
Reviva Pharmaceuticals aims to improve schizophrenia treatment with Brilaroxazine, showing promising Phase 3 data but needing funding for a second trial to meet FDA requirements. Reviva should announce open label safety and biomarker efficacy data from its previous Phase 3 trial any day now. The company faces financial challenges, requiring either dilution or a partnership to fund the next Phase 3 trial and continue operations. |
seekingalpha.com |
2024-12-11 17:37:00 |
Czytaj oryginał (ang.) |
| Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights |
– 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial – – Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine's improvement on negative symptoms and other key symptom domains of schizophrenia – – Topline data from OLE trial expected in December 2024 – CUPERTINO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today reported financial results for the third quarter ended September 30, 2024 and summarized recent business highlights. |
globenewswire.com |
2024-11-14 19:25:00 |
Czytaj oryginał (ang.) |
| Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024 |
CUPERTINO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that positive speech latency data for brilaroxazine in schizophrenia from the Phase 3 RECOVER trial will be presented as a poster presentation at the CNS Summit 2024, taking place November 10-13, in Boston, Massachusetts. |
globenewswire.com |
2024-11-06 10:00:00 |
Czytaj oryginał (ang.) |
| Reviva to Participate in the UBS Global Healthcare Conference |
CUPERTINO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a fireside chat at the UBS Global Healthcare Conference, taking place November 11-14, 2024, in Rancho Palos Verdes, CA. |
globenewswire.com |
2024-10-31 10:00:00 |
Czytaj oryginał (ang.) |
| Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit |
CUPERTINO, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit, taking place virtually October 15-17, 2024. |
globenewswire.com |
2024-10-08 12:00:00 |
Czytaj oryginał (ang.) |
| Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference |
CUPERTINO, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a panel discussion at the 3rd Annual ROTH Healthcare Opportunities Conference, taking place October 9, 2024, in New York, NY. |
globenewswire.com |
2024-10-02 12:30:00 |
Czytaj oryginał (ang.) |
| Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules |
CUPERTINO, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the pricing of an underwritten offering of 4,761,905 shares of the Company's common stock (or pre-funded warrants in lieu thereof) and investor warrants to purchase up to 4,761,905 shares of common stock. The combined offering price of each share of common stock and accompanying warrant sold in the offering (including the pricing for the warrant repricing described below) will be equal to $1.05, priced at-the-market under the Nasdaq rules. The combined offering price of each pre-funded warrant and accompanying warrant sold in the offering will be equal to $1.0499. The warrants have an exercise price of $0.7964 per share, will be immediately exercisable and will expire five years following the date of issuance. The pre-funded warrants have an exercise price of $0.0001 per share, will be immediately exercisable and may be exercised at any time after their original issuance. The offering is expected to close on or about August 22, 2024, subject to customary closing conditions. |
globenewswire.com |
2024-08-21 10:00:00 |
Czytaj oryginał (ang.) |
| Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension |
- Patent covers brilaroxazine use for treating pulmonary hypertension (PH), pulmonary arterial hypertension (PAH) in any patients including treating PH in patients with chronic obstructive pulmonary disease (COPD) or sickle cell disease (SCD) |
globenewswire.com |
2024-07-09 12:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH |
NEW YORK, NY / ACCESSWIRE / June 1, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Reviva Pharmaceuticals Holdings, Inc. ("Reviva" or the "Company") (NASDAQ:RVPH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accesswire.com |
2024-06-01 16:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH |
NEW YORK , May 30, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Reviva Pharmaceuticals Holdings, Inc. ("Reviva" or the "Company") (NASDAQ: RVPH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2024-05-30 23:20:00 |
Czytaj oryginał (ang.) |
| Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules |
CUPERTINO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it has closed its previously announced registered direct offering for the sale and issuance of 1,898,734 shares of the Company's common stock and warrants to purchase up to 1,898,734 shares of common stock at a combined offering price of $1.58 per share of common stock and accompanying warrant priced at-the-market under the Nasdaq rules. The warrants have an exercise price of $1.455 per share, are immediately exercisable and will expire five years following the date of issuance. |
globenewswire.com |
2024-05-29 20:45:00 |
Czytaj oryginał (ang.) |
| Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules |
CUPERTINO, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it has entered into a definitive agreement for the sale and issuance of 1,898,734 shares of the Company's common stock and warrants to purchase up to 1,898,734 shares of common stock at a combined offering price of $1.58 per share of common stock and accompanying warrant in a registered direct offering priced at-the-market under the Nasdaq rules. The warrants have an exercise price of $1.455 per share, will be immediately exercisable and will expire five years following the date of issuance. The closing of the offering is expected to occur on or about May 29, 2024, subject to the satisfaction of customary closing conditions. |
globenewswire.com |
2024-05-28 12:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH |
NEW YORK , May 23, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Reviva Pharmaceuticals Holdings, Inc. ("Reviva" or the "Company") (NASDAQ: RVPH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2024-05-23 16:41:00 |
Czytaj oryginał (ang.) |
| Reviva to Participate in the BIO International Convention |
CUPERTINO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a panel discussion at the BIO International Convention, taking place June 3-6, 2024, in San Diego, CA. |
globenewswire.com |
2024-05-21 12:00:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH |
NEW YORK , May 16, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Reviva Pharmaceuticals Holdings, Inc. ("Reviva" or the "Company") (NASDAQ: RVPH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2024-05-17 00:55:00 |
Czytaj oryginał (ang.) |
| Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia |
– 358 enrolled and 223 patients currently on treatment across sites in the USA, Europe and Asia – – Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia – – Topline data from 1-year open-label extension (OLE) trial expected in Q4 2024 – CUPERTINO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced an enrollment update to the ongoing 1-year open-label extension (OLE) study evaluating the long-term safety and tolerability of brilaroxazine in patients with schizophrenia. |
globenewswire.com |
2024-05-15 12:00:00 |
Czytaj oryginał (ang.) |
| Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights |
– Gained alignment with U.S. Food and Drug Administration (FDA) on brilaroxazine clinical trials for New Drug Application (NDA) submission in schizophrenia – |
globenewswire.com |
2024-05-14 12:00:00 |
Czytaj oryginał (ang.) |
| Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference |
CUPERTINO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva, will present new efficacy data on brilaroxazine in an animal model of idiopathic pulmonary fibrosis as part of a late-breaking poster presentation at the 2024 American Thoracic Society (ATS) International Conference, to be held in San Diego, CA, May 17-22, 2024. |
globenewswire.com |
2024-05-13 12:00:00 |
Czytaj oryginał (ang.) |
| RVPH INVESTOR NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPH |
NEW YORK , May 10, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) resulting from allegations that Reviva Pharmaceuticals may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Reviva Pharmaceuticals securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. |
prnewswire.com |
2024-05-11 00:41:00 |
Czytaj oryginał (ang.) |